Hims and Hers Health (HIMS) will begin offering a compounded version of Novo Nordisk’s (NVO) new Wegovy pill at an introductory price of $49 per month, or about $100 less than the brand name, reported Reuters, citing the online telehealth company. Following the lower one-time payment, patients at Hims with a five-month subscription will pay $99 per month thereafter versus the $199 Novo will charge, the report noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers price target lowered to $60 from $85 at BTIG
- Hims and Hers Health call volume above normal and directionally bullish
- Option traders moderately bearish in Hims and Hers Health with shares down 2.63%
- Mixed options sentiment in Hims and Hers Health with shares down 0.67%
- UAA, MARA, HIMS: The 10 Most Shorted Stocks in the Market